Literature DB >> 16787278

Structure-activity relationships of K(ATP) channel openers.

Raimund Mannhold1.   

Abstract

Given their many physiological functions, K(ATP) channels represent promising drug targets. Sulfonylureas like glibenclamide block K(ATP) channels; they are used in the therapy of type 2 diabetes. Openers of K(ATP) channels (KCOs) e.g. relax smooth muscle and induce hypotension. KCOs are chemically heterogeneous and include as different classes as the benzopyrans, cyanoguanidines, thioformamides, thiadiazines and pyridyl nitrates. Examples for new chemical entities more recently developed as KCOs include cyclobutenediones, dihydropyridine related structures, and tertiary carbinols. Structure-activity relationships of the main chemical classes of KCOs are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787278     DOI: 10.2174/156802606777323647

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  The inflammasome: in memory of Dr. Jurg Tschopp.

Authors:  M Dagenais; A Skeldon; M Saleh
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters.

Authors:  C-C Shieh; M E Brune; S A Buckner; K L Whiteaker; E J Molinari; I A Milicic; A C Fabiyi; A Daza; J D Brioni; W A Carroll; K Matsushita; M Yamada; Y Kurachi; M Gopalakrishnan
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

Review 3.  The role of ATP-sensitive potassium channels in cellular function and protection in the cardiovascular system.

Authors:  Andrew Tinker; Qadeer Aziz; Alison Thomas
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

4.  The Concise Guide to PHARMACOLOGY 2013/14: ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.